Literature DB >> 3609301

Physiological variant of antithrombin-III lacks carbohydrate sidechain at Asn 135.

S O Brennan, P M George, R E Jordan.   

Abstract

Both normal antithrombin-III (AT-III alpha) and the high heparin affinity form (AT-III beta) were isolated from pooled human plasma. AT-III beta had a lower negative charge and lower molecular mass than AT-III alpha. Sialidase and endo-F digestion indicated that the inherent difference resided in the oligosaccharide component of the molecule. CNBr fragmentation showed there was an oligosaccharide sidechain missing between residues 104 and 251, subdigestion with trypsin indicated that Asn 135 was not glycosylated in AT-III beta. Chromatography of total tryptic digests on concanavalin A-Sepharose confirmed that the high heparin affinity form of antithrombin lacked an oligosaccharide moiety at Asn 135.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3609301     DOI： 10.1016/0014-5793(87)80266-1

Source DB:  PubMed          Journal:  FEBS Lett        ISSN： 0014-5793            Impact factor:   4.124


  11 in total

1.  Pleiotropic effects of antithrombin strand 1C substitution mutations.

Authors:  D A Lane; R J Olds; J Conard; M Boisclair; S C Bock; M Hultin; U Abildgaard; H Ireland; E Thompson; G Sas
Journal:  J Clin Invest       Date:  1992-12       Impact factor: 14.808

2.  Decreased affinity of recombinant antithrombin for heparin due to increased glycosylation.

Authors:  I Björk; K Ylinenjärvi; S T Olson; P Hermentin; H S Conradt; G Zettlmeissl
Journal:  Biochem J       Date:  1992-09-15       Impact factor: 3.857

3.  Albumin Redhill (-1 Arg, 320 Ala----Thr): a glycoprotein variant of human serum albumin whose precursor has an aberrant signal peptidase cleavage site.

Authors:  S O Brennan; T Myles; R J Peach; D Donaldson; P M George
Journal:  Proc Natl Acad Sci U S A       Date:  1990-01       Impact factor: 11.205

4.  Proposed heparin binding site in antithrombin based on arginine 47. A new variant Rouen-II, 47 Arg to Ser.

Authors:  J Y Borg; M C Owen; C Soria; J Soria; J Caen; R W Carrell
Journal:  J Clin Invest       Date:  1988-04       Impact factor: 14.808

5.  Protective effect of a newly developed fucose-deficient recombinant antithrombin against histone-induced endothelial damage.

Authors:  Toshiaki Iba; Tatsuhiko Hirota; Koichi Sato; Isao Nagaoka
Journal:  Int J Hematol       Date:  2018-01-20       Impact factor: 2.490

6.  HS3ST1 genotype regulates antithrombin's inflammomodulatory tone and associates with atherosclerosis.

Authors:  Nicole C Smits; Takashi Kobayashi; Pratyaksh K Srivastava; Sladjana Skopelja; Julianne A Ivy; Dustin J Elwood; Radu V Stan; Gregory J Tsongalis; Frank W Sellke; Peter L Gross; Michael D Cole; James T DeVries; Aaron V Kaplan; John F Robb; Scott M Williams; Nicholas W Shworak
Journal:  Matrix Biol       Date:  2017-01-23       Impact factor: 11.583

7.  Elimination of glycosylation heterogeneity affecting heparin affinity of recombinant human antithrombin III by expression of a beta-like variant in baculovirus-infected insect cells.

Authors:  E Ersdal-Badju; A Lu; X Peng; V Picard; P Zendehrouh; B Turk; I Björk; S T Olson; S C Bock
Journal:  Biochem J       Date:  1995-08-15       Impact factor: 3.857

8.  The complete amino acid sequence of bovine antithrombin (ATIII).

Authors:  H Mejdoub; M Le Ret; Y Boulanger; M Maman; J Choay; J Reinbolt
Journal:  J Protein Chem       Date:  1991-04

9.  Variation of fibrinogen oligosaccharide structure in the acute phase response: Possible haemorrhagic implications.

Authors:  Stephen O Brennan
Journal:  BBA Clin       Date:  2015-03-04

10.  Comparison of biological activities of human antithrombins with high-mannose or complex-type nonfucosylated N-linked oligosaccharides.

Authors:  Tsuyoshi Yamada; Yutaka Kanda; Makoto Takayama; Akitoshi Hashimoto; Tsutomu Sugihara; Ai Satoh-Kubota; Eri Suzuki-Takanami; Keiichi Yano; Shigeru Iida; Mitsuo Satoh
Journal:  Glycobiology       Date:  2016-01-07       Impact factor: 4.313
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.